Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Au(III) complexes of symmetrical tetradentate Schiff base ligands: Synthesis, characterization, anticancer/antioxidant potency, in silico prediction, and catalase binding properties

Au(III) complexes of symmetrical tetradentate Schiff base ligands: Synthesis, characterization,... Two new gold(III) complexes, [AuL1]Cl3, A, and [AuL2]Cl3, B, were synthesized and characterized. DFT calculations showed square planar geometry for both complexes. Antioxidant results showed that the ability of compounds to inhibit DPPH• is as follows: A > B > L2 > L1. The anticancer assay showed that both complexes have the ability to inhibit the growth of HCT116 colon cancer cell lines, but B shows a relatively better effect than cisplatin. The interaction effects of A and B on the activity and structure of the bovine liver catalase (BLC) were investigated by spectroscopic techniques and molecular docking. Both complexes were able to change the performance and structure of BLC; B has a greater effect on BLC activity, so at concentration of 2 μM, A and B inhibit initial BLC activity by 92.2% and 55.6%, respectively. The interaction mechanism of A and B with BLC was also different; A interacted mostly with van der Waals interactions and hydrogen bonds, but the most important forces for B was hydrophobic interactions. According to docking results, both complexes prefer the domain III of BLC, but B has higher affinity toward BLC than A, which supports the results of spectroscopic and FMO analysis. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Organometallic Chemistry Wiley

Au(III) complexes of symmetrical tetradentate Schiff base ligands: Synthesis, characterization, anticancer/antioxidant potency, in silico prediction, and catalase binding properties

Download PDF
17 pages

Loading next page...
 
/lp/wiley/au-iii-complexes-of-symmetrical-tetradentate-schiff-base-ligands-m4pI7XWCIC

References (43)

Publisher
Wiley
Copyright
© 2023 John Wiley & Sons, Ltd.
ISSN
0268-2605
eISSN
1099-0739
DOI
10.1002/aoc.7139
Publisher site
See Article on Publisher Site

Abstract

Two new gold(III) complexes, [AuL1]Cl3, A, and [AuL2]Cl3, B, were synthesized and characterized. DFT calculations showed square planar geometry for both complexes. Antioxidant results showed that the ability of compounds to inhibit DPPH• is as follows: A > B > L2 > L1. The anticancer assay showed that both complexes have the ability to inhibit the growth of HCT116 colon cancer cell lines, but B shows a relatively better effect than cisplatin. The interaction effects of A and B on the activity and structure of the bovine liver catalase (BLC) were investigated by spectroscopic techniques and molecular docking. Both complexes were able to change the performance and structure of BLC; B has a greater effect on BLC activity, so at concentration of 2 μM, A and B inhibit initial BLC activity by 92.2% and 55.6%, respectively. The interaction mechanism of A and B with BLC was also different; A interacted mostly with van der Waals interactions and hydrogen bonds, but the most important forces for B was hydrophobic interactions. According to docking results, both complexes prefer the domain III of BLC, but B has higher affinity toward BLC than A, which supports the results of spectroscopic and FMO analysis.

Journal

Applied Organometallic Chemistry – Wiley

Published: Jul 1, 2023

Keywords: anticancer; catalase; Schiff base complexes

There are no references for this article.